nimodipine has been researched along with Chronic Disease in 11 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the influence of nimodipine on non-migrainous vascular headache in patients with chronic cerebral ischemia." | 9.06 | Nimodipine in the treatment of headache in chronic cerebral ischemia. ( Hadjiev, D; Ivanova, L; Velcheva, I, 1986) |
| "The aim of this study was to evaluate the influence of nimodipine on non-migrainous vascular headache in patients with chronic cerebral ischemia." | 5.06 | Nimodipine in the treatment of headache in chronic cerebral ischemia. ( Hadjiev, D; Ivanova, L; Velcheva, I, 1986) |
| "Ninety-one patients with chronic migraine were randomly divided into four groups: in the control group (group A, 22 cases in total), nimodipine was used in the treatment of chronic migraine for two months; in the infrared polarized light therapy group (group B, 22 cases in total), infrared polarized light was adopted in the treatment of chronic migraine for 50-60d; in the botulinum toxin treatment group (group C, 24 cases in total), ultrasound-and-hyponome-guided type A botulinum toxin was injected into frontal, temporal, and occipital muscles in treating chronic migraine; in the joint treatment group (group D, 23 cases in total), ultrasound-and-hyponome-guided type A botulinum toxin injection in group C and infrared polarized light in group B were both used here in the treatment of chronic migraine." | 2.80 | Efficacy of type a botulinum toxin injections and infrared polarized light on treating chronic migraine. ( Chen, HX; Ding, XD; Hong, Y; Huang, L; Song, JH; Zhang, GB, 2015) |
| "Nimodipine treatment attenuated CCH induced tau phosphorylation by up-regulating expression of miR-132." | 1.48 | Nimodipine attenuates tau phosphorylation at Ser396 via miR-132/GSK-3β pathway in chronic cerebral hypoperfusion rats. ( Chen, Y; Liu, X; Tan, Z; Xie, W; Zhu, Y, 2018) |
| "In aneurysmal subarachnoid haemorrhage cerebral vasospasm leads to clinical worsening and poor outcome." | 1.46 | Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm. ( Doukas, A; Jansen, O; Larsen, N; Mehdorn, M; Stopfer, A; Synowitz, M; von der Brelie, C, 2017) |
| "LPS-infused rats had significant memory deficits in the Morris water maze, and this deficit was ameliorated by treatment with nimodipine." | 1.42 | Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation. ( Adzovic, L; Crockett, AM; D'Angelo, HM; Hopp, SC; Kaercher, RM; Royer, SE; Wenk, GL, 2015) |
| "Nimodipine was administered postoperatively by subcutaneous injection of 1 ml/0." | 1.27 | Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm. ( Grace, MG; Lewis, PJ; Nosko, MG; Tanabe, T; Weir, BK, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, Z | 1 |
| Chen, Y | 1 |
| Xie, W | 1 |
| Liu, X | 1 |
| Zhu, Y | 2 |
| Li, H | 1 |
| Yang, X | 1 |
| Shi, W | 1 |
| Ma, Z | 1 |
| Feng, G | 1 |
| Wang, Q | 1 |
| Shen, L | 1 |
| Xie, C | 1 |
| Hopp, SC | 1 |
| D'Angelo, HM | 1 |
| Royer, SE | 1 |
| Kaercher, RM | 1 |
| Crockett, AM | 1 |
| Adzovic, L | 1 |
| Wenk, GL | 1 |
| Song, JH | 1 |
| Zhang, GB | 1 |
| Ding, XD | 1 |
| Huang, L | 1 |
| Hong, Y | 1 |
| Chen, HX | 1 |
| von der Brelie, C | 1 |
| Doukas, A | 1 |
| Stopfer, A | 1 |
| Larsen, N | 1 |
| Mehdorn, M | 1 |
| Synowitz, M | 1 |
| Jansen, O | 1 |
| Canadè, V | 1 |
| Catapano, F | 1 |
| Muraca, L | 1 |
| Cosentino, A | 1 |
| Lewis, PJ | 1 |
| Weir, BK | 1 |
| Nosko, MG | 1 |
| Tanabe, T | 1 |
| Grace, MG | 1 |
| Hadjiev, D | 1 |
| Velcheva, I | 1 |
| Ivanova, L | 1 |
| Cosmi, F | 1 |
| Caresia, L | 1 |
| Panebianco, G | 1 |
| Gioia, AE | 1 |
| White, RP | 1 |
| Bakhtian, B | 1 |
| Robertson, JT | 1 |
| Zabramski, J | 1 |
| Spetzler, RF | 1 |
| Bonstelle, C | 1 |
2 trials available for nimodipine and Chronic Disease
| Article | Year |
|---|---|
Efficacy of type a botulinum toxin injections and infrared polarized light on treating chronic migraine.
Topics: Adult; Botulinum Toxins, Type A; Chronic Disease; Cross-Sectional Studies; Disability Evaluation; Fe | 2015 |
Nimodipine in the treatment of headache in chronic cerebral ischemia.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Chronic Disease; Clinical Trials as Topic; Double-Blind Met | 1986 |
9 other studies available for nimodipine and Chronic Disease
| Article | Year |
|---|---|
Nimodipine attenuates tau phosphorylation at Ser396 via miR-132/GSK-3β pathway in chronic cerebral hypoperfusion rats.
Topics: Animals; Apoptosis; Brain Ischemia; Cerebral Cortex; Chronic Disease; Gene Expression Regulation, En | 2018 |
Protective effects of nimodipine on cerebrovascular function in chronic alcoholic encephalopathy.
Topics: Alcohol Amnestic Disorder; Alcohol Drinking; Animals; Arterioles; Cerebellum; Cerebral Arteries; Chr | 2014 |
Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation.
Topics: AIDS-Related Complex; Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Calcium Chan | 2015 |
Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm.
Topics: Cerebral Angiography; Chronic Disease; Disease Progression; Echoencephalography; Female; Humans; Inf | 2017 |
[Effects of nimodipine on mental deterioration in subjects with chronic cerebrovascular pathology].
Topics: Aged; Aged, 80 and over; Cerebrovascular Disorders; Chronic Disease; Humans; Neurocognitive Disorder | 1991 |
Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm.
Topics: Animals; Cerebral Angiography; Chronic Disease; Female; Injections, Spinal; Ischemic Attack, Transie | 1988 |
[Treatment of chronic cerebrovascular insufficiency: comparison of nimodipine and dihydroergotoxine].
Topics: Aged; Cerebrovascular Disorders; Chronic Disease; Dihydroergotoxine; Drug Evaluation; Female; Humans | 1986 |
Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm.
Topics: Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal; Dogs; Female; Injections | 1985 |
Chronic cerebral vasospasm: effect of calcium antagonists.
Topics: Animals; Cerebral Angiography; Chronic Disease; Disease Models, Animal; Dogs; Injections; Ischemic A | 1986 |